Last updated: September 18, 2026
Gadoxetate disodium is a liver-specific gadolinium-based contrast agent sold primarily as Eovist in the United States and Primovist in Europe and other markets. Bayer owns the principal branded commercial franchise. The product is differentiated by hepatocyte uptake, which supports detection and characterization of focal liver lesions during magnetic resonance imaging.
Its commercial profile is mature rather than growth-oriented. Core composition and regulatory exclusivity have expired in major markets, while clinical differentiation, radiology adoption, manufacturing controls, and distribution remain the main commercial barriers. Bayer does not report Eovist or Primovist revenue as a standalone line item, so product-level revenue and margin estimates are not publicly verifiable.
What is gadoxetate disodium used for?
Gadoxetate disodium is an extracellular and hepatobiliary MRI contrast agent used for liver imaging. It is administered intravenously and is marketed at a concentration of 0.25 mmol/mL.
The agent has two clinically relevant phases:
- The dynamic vascular phase, which provides information similar to other gadolinium-based contrast agents.
- The hepatobiliary phase, in which uptake by functioning hepatocytes improves visualization of liver tissue and certain lesions.
The hepatobiliary phase is the principal source of product differentiation. Gadoxetate disodium is used in the evaluation of liver lesions, including suspected hepatocellular carcinoma, metastases, focal nodular hyperplasia, and other hepatic abnormalities. Product labeling limits its use to diagnostic imaging; it is not a therapeutic product. The U.S. label identifies Eovist as a gadolinium-based contrast agent indicated for adults undergoing MRI of the liver to detect and characterize lesions with abnormal vascularity or hepatocyte function (FDA, 2023).
How does gadoxetate disodium compare with other liver MRI agents?
| Product |
Active ingredient |
Hepatobiliary uptake |
Principal commercial owner |
Market position |
| Eovist/Primovist |
Gadoxetate disodium |
Yes |
Bayer |
Liver-specific, established product |
| MultiHance |
Gadobenate dimeglumine |
Partial, delayed |
Bracco |
Alternative with limited hepatobiliary uptake |
| Gadavist/Gadovist |
Gadobutrol |
No meaningful hepatobiliary phase |
Bayer |
Broad-use extracellular agent |
| Dotarem/Clariscan |
Gadoterate meglumine |
No meaningful hepatobiliary phase |
Guerbet/GE HealthCare, depending on market |
Macrocyclic extracellular agent |
| ProHance |
Gadoteridol |
No meaningful hepatobiliary phase |
Bracco |
Macrocyclic extracellular agent |
Gadoxetate disodium has a narrower indication base than general-purpose extracellular agents but a stronger product rationale in dedicated liver MRI. Its competitive position depends on whether a healthcare system values hepatobiliary-phase information, the availability of trained radiologists, scanner capacity, reimbursement, and contrast-agent procurement pricing.
When did gadoxetate disodium lose exclusivity?
Gadoxetate disodium lost meaningful market exclusivity years ago. The U.S. product was approved in 2008, and the five-year new chemical entity exclusivity period would have expired in 2013, subject to the statutory framework and any applicable pediatric extension. The product’s original composition and use patent protection also expired or reached the end of its enforceable term before the current market period.
| Milestone |
Approximate timing |
Commercial effect |
| European introduction of Primovist |
2004 |
Established first major commercial market |
| U.S. FDA approval of Eovist |
2008 |
Opened the U.S. market |
| U.S. five-year NCE exclusivity expiration |
2013 |
Removed the principal FDA regulatory exclusivity barrier |
| Original patent protection |
Mid-to-late 2010s, depending on jurisdiction and patent term adjustments |
Reduced composition-of-matter protection |
| Current market phase |
Mature |
Price, supply, clinical preference, and procurement drive competition |
The exact expiration date depends on the jurisdiction, patent family, patent-term adjustment or extension, and the specific claim. A single “compound patent expiration date” should not be used as a substitute for a jurisdiction-by-jurisdiction review of the patent register.
What patents protect gadoxetate disodium?
The historical patent estate centered on gadolinium complexes containing hepatobiliary targeting functionality, including gadolinium-EOB-DTPA chemistry and related pharmaceutical compositions. Bayer and affiliated entities were associated with the original development and commercialization of the product.
The principal protection categories were:
- Composition-of-matter claims covering the gadolinium complex.
- Pharmaceutical-composition claims covering injectable formulations.
- Manufacturing and purification claims.
- Diagnostic-use claims involving liver MRI.
- Potential claims covering dosage, administration, or imaging protocols.
The original composition claims provided the most valuable protection. Formulation and method-of-use claims were commercially less durable because the active ingredient’s chemical identity and diagnostic role were already established, while later claims faced narrower scope and greater validity exposure.
What is the Orange Book status of Eovist?
Eovist is listed in FDA drug databases as a prescription injectable contrast agent under NDA 022090. The relevant U.S. regulatory record is the FDA-approved labeling and the Orange Book entry for the reference product (FDA, 2023; FDA, 2024).
The commercial importance of Orange Book listings has declined because the product’s primary exclusivity period has ended. Any current patent listing must be assessed against the specific Orange Book edition and the listed patent’s status. Product-level Orange Book information does not establish that all historical Bayer patents remain enforceable.
Eovist is a small-molecule drug, not a biologic. It therefore does not have a biosimilar pathway under the Public Health Service Act. Competitive entry would generally proceed through an abbreviated new drug application, a full 505(b)(2) application, or a comparable national procedure outside the United States.
How many patents cover gadoxetate disodium today?
The historical estate contains multiple patent families, but the number of currently enforceable claims cannot be stated reliably without a live patent-register review for each jurisdiction. The commercially important question is whether any unexpired patent blocks an ANDA or a generic launch.
In the United States, the original product is no longer protected by a broad, early-stage composition monopoly. Any remaining enforceable rights would more likely involve a specific formulation, manufacturing process, diagnostic method, or later-filed improvement. Such patents generally present a narrower barrier than a valid composition-of-matter patent.
What formulations are protected by gadoxetate disodium patents?
The marketed formulation is an aqueous injectable solution containing gadoxetate disodium at 0.25 mmol/mL. Formulation-related patent exposure may include:
- Concentration and pH ranges.
- Stabilization and impurity-control parameters.
- Container-closure systems.
- Sterilization and filling processes.
- Manufacturing conditions that control free gadolinium and degradation products.
For generic entry, formulation patents are relevant only if they are listed, enforceable, and infringed by the proposed product. Manufacturing patents can still affect supply economics even when they do not prevent regulatory approval.
Are there Paragraph IV challenges to Eovist?
No major, widely reported Paragraph IV litigation campaign has established a durable current patent barrier around Eovist. The absence of prominent litigation is consistent with a mature product whose central patent protection has expired.
A Paragraph IV challenge remains legally possible if a listed patent exists and a generic applicant certifies that the patent is invalid, unenforceable, or not infringed. The practical risk is limited by the commercial size of the opportunity. A generic applicant must weigh:
- The cost of developing a sterile injectable contrast agent.
- The relatively specialized liver-imaging market.
- Bayer’s ability to defend any remaining formulation or use claims.
- Procurement-driven price erosion.
- Manufacturing and quality-system requirements.
- The availability of alternative contrast agents.
No major settlement agreement involving Eovist has become a central feature of the product’s current commercial outlook in publicly available regulatory and litigation reporting.
What is the FDA regulatory status of gadoxetate disodium?
Eovist is FDA-approved for adult liver MRI. The product carries class-specific gadolinium-based contrast-agent warnings, including risks relating to nephrogenic systemic fibrosis in susceptible patients and gadolinium retention. The label directs healthcare professionals to select and administer contrast agents based on the patient’s renal status, imaging need, and risk profile (FDA, 2023).
Regulatory status is commercially important because contrast agents are sterile injectable products. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence or an applicable alternative under FDA requirements. Manufacturing consistency, particulate control, sterility assurance, container integrity, and impurity specifications are significant approval considerations.
The agent’s clinical value also depends on the hepatobiliary phase, which requires an imaging protocol and delayed acquisition. Generic substitution should not materially alter the imaging characteristics of the active ingredient, concentration, administration, or labeling.
What companies are challenging Bayer in the gadoxetate disodium market?
Competition is divided into direct and indirect categories.
Direct generic competitors
The main direct threat comes from manufacturers seeking to market gadoxetate disodium injection after the original exclusivity period. A generic product can compete on acquisition price if it receives approval and secures hospital, imaging-center, or group-purchasing contracts.
The identity and market share of generic suppliers can change by country and procurement cycle. Unlike high-volume oral medicines, contrast-agent markets often have a small number of qualified suppliers, and a regulatory approval does not guarantee material commercial penetration.
Branded contrast-agent competitors
Bayer competes with Bracco, Guerbet, GE HealthCare and other diagnostic-imaging suppliers across the broader MRI contrast market. These companies do not need to replicate gadoxetate disodium to pressure the product. They can compete through:
- Portfolio contracting.
- Lower-cost extracellular agents.
- Hospital formulary access.
- Scanner and radiology relationships.
- Supply reliability.
- Clinical education and workflow integration.
The strongest indirect competition comes from general-purpose agents used when hepatobiliary-phase information is not necessary.
How strong is the patent estate for gadoxetate disodium?
The current patent estate is weak relative to a newly launched pharmaceutical product. The original composition and regulatory exclusivity have expired, and the product has been marketed for approximately two decades in its earliest major jurisdictions.
Patent strength can be summarized as follows:
| Protection category |
Current strategic strength |
| Original composition patent |
Low after expiration |
| NCE regulatory exclusivity |
Expired |
| Broad method-of-use protection |
Limited and jurisdiction-dependent |
| Formulation patents |
Potentially relevant but narrower |
| Manufacturing patents |
Potential supply barrier, not necessarily a market block |
| Trade secrets and know-how |
Moderate operational value |
| Regulatory and quality history |
Meaningful practical advantage |
| Brand and radiologist familiarity |
Moderate commercial value |
Bayer’s strongest remaining advantages are likely operational rather than patent-based: established regulatory documentation, manufacturing experience, global distribution, product recognition, and existing customer relationships.
What is the financial trajectory for gadoxetate disodium?
Public financial disclosure does not provide a verified standalone revenue series for Eovist or Primovist. Bayer reports pharmaceutical sales at broader business-unit, therapeutic-area, or product-cluster levels rather than consistently disclosing the revenue, gross margin, or operating profit of this individual contrast agent (Bayer AG, 2023, 2024).
The financial trajectory is therefore best characterized directionally:
Launch and adoption phase
The product gained value from a distinct clinical use case: liver MRI with hepatobiliary-phase imaging. Adoption was supported by its ability to provide information that conventional extracellular agents could not provide as efficiently in a single examination.
Mature branded phase
After approval in the United States and expansion across international markets, revenue likely depended on procedure volume, radiology adoption, reimbursement, and Bayer’s contrast-agent distribution platform. The product’s specialized indication limited total market size but supported premium positioning relative to commodity extracellular agents.
Post-exclusivity phase
Following loss of exclusivity, pricing power weakened. Revenue exposure shifted from patent-protected margin to:
- Installed clinical use.
- Brand preference.
- Supply reliability.
- Hospital contracts.
- Geographic availability.
- Generic penetration.
- The relative growth of liver MRI.
Current financial outlook
The most defensible outlook is stable-to-declining branded revenue, with upside from increased liver MRI utilization and downside from generic price competition and hospital procurement pressure. A sudden collapse is less likely than gradual erosion because the product has a differentiated hepatobiliary use and is used in specialized imaging protocols.
The product is unlikely to be a major growth driver for Bayer’s pharmaceutical division. Its value is more consistent with a mature portfolio asset that generates recurring revenue from an established diagnostic franchise.
What revenue exposure does Bayer have?
Bayer’s revenue exposure is concentrated in its pharmaceuticals business and radiology portfolio, but the company does not identify gadoxetate disodium as a separately material reporting segment. This limits the ability to calculate:
- Product-specific annual sales.
- Product-level EBITDA.
- Geographic revenue contribution.
- Margin erosion from generic entry.
- Bayer’s exact exposure to hospital procurement discounts.
The commercial exposure is likely modest relative to Bayer’s largest prescription products. Its strategic value may exceed its reported revenue contribution because the product supports Bayer’s broader imaging-contrast portfolio and customer relationships.
What generic launch scenarios exist for gadoxetate disodium?
Scenario 1: No material generic entry
Bayer retains most volume because the market is specialized, supplier qualification is difficult, and generic manufacturers see insufficient returns. Prices decline through contracting rather than through broad substitution.
Scenario 2: One approved generic supplier
A single entrant gains access to selected hospital systems and imaging centers. Bayer experiences moderate price pressure, while the generic supplier earns limited but defensible share.
Scenario 3: Multiple generic entrants
Several suppliers compete for institutional contracts. Price erosion accelerates, Bayer’s branded share declines, and the market begins to resemble other mature injectable contrast categories.
Scenario 4: Geographic fragmentation
Generic entry occurs in some countries but not others because of different registration requirements, reimbursement policies, local patents, and procurement structures. Bayer retains stronger branded economics in markets where the product has high clinical penetration or limited approved competition.
What manufacturing and intellectual-property barriers remain?
The principal barriers are technical and regulatory rather than foundational patent barriers.
Gadoxetate disodium is a complex chelated gadolinium compound. A commercial supplier must control:
- Chelation completeness.
- Free gadolinium levels.
- Related substances and degradation products.
- Sterility and endotoxin specifications.
- Solution stability.
- Container compatibility.
- Batch-to-batch consistency.
- Global pharmacopoeial and regulatory requirements.
These requirements raise development costs and can delay commercial launch. They do not necessarily prevent entry by a well-capitalized generic manufacturer with experience in sterile injectables and contrast media.
Trade secrets and process knowledge may therefore have greater practical value than expired composition patents. A competitor can obtain approval without copying Bayer’s exact manufacturing process, but it must produce a chemically and clinically acceptable equivalent.
What litigation and settlement risks affect gadoxetate disodium?
The historic litigation risk was highest before and around loss of exclusivity. Current litigation risk is more likely to involve:
- Patent infringement claims over a later formulation or process patent.
- ANDA litigation if an Orange Book-listed patent remains relevant.
- Product-liability claims involving gadolinium retention or renal complications.
- Manufacturing and supply disputes.
- Regulatory challenges to generic equivalence.
There is no established current settlement framework that materially delays broad generic access to gadoxetate disodium. Any future settlement would require review of the asserted patent, the agreed launch date, the scope of the generic product, and any permitted authorized-generic arrangement.
How does gadoxetate disodium compare with other mature contrast agents?
| Factor |
Gadoxetate disodium |
General extracellular MRI agents |
| Clinical differentiation |
High for hepatobiliary imaging |
Broad but less liver-specific |
| Addressable market |
Narrower |
Larger |
| Patent strength |
Mature and largely expired |
Varies by molecule |
| Generic substitution risk |
Moderate |
Often higher in commodity products |
| Pricing power |
Supported by specialty use |
More procurement-sensitive |
| Manufacturing complexity |
High sterile injectable and chelate controls |
High, but established for many agents |
| Growth driver |
Liver MRI adoption |
Overall MRI volume and hospital contracts |
| Main commercial risk |
Specialized-market size and generic entry |
Price competition and portfolio substitution |
Gadoxetate disodium is more differentiated than a standard extracellular agent but serves a smaller market. That combination can preserve clinical relevance while limiting revenue growth.
Key Takeaways
- Gadoxetate disodium is a mature, liver-specific MRI contrast agent sold as Eovist and Primovist.
- Bayer is the principal branded sponsor and commercial owner.
- U.S. FDA approval occurred in 2008; five-year new chemical entity exclusivity expired in 2013.
- Original composition and broad regulatory exclusivity no longer provide a durable market barrier.
- Current patent value, if any, is more likely to reside in formulation, manufacturing, or narrow method-of-use claims.
- The product is a small molecule, so biosimilar risk does not apply. Generic and 505(b)(2) competition are the relevant pathways.
- Bayer does not publicly report standalone Eovist or Primovist revenue, preventing a verified product-level financial series.
- The likely financial trajectory is mature to declining branded revenue, moderated by the product’s specialized hepatobiliary use.
- Manufacturing complexity, sterile injectable requirements, quality controls, and procurement access remain practical barriers to entry.
- The principal long-term risks are generic price erosion, hospital contracting pressure, and substitution by broader MRI contrast agents.
FAQs About Gadoxetate Disodium Patents and Market Outlook
Is gadoxetate disodium still patent-protected?
Broad original protection has expired in major markets. Narrower formulation, process, or method-of-use patents must be assessed by jurisdiction and claim.
Does gadoxetate disodium have biosimilar competition?
No. Gadoxetate disodium is a small-molecule drug. Competition would generally come from generic injectable products, not biosimilars.
Is Eovist listed in the FDA Orange Book?
Yes. Eovist is identified in FDA drug databases under NDA 022090. The current significance of any patent listing depends on the specific Orange Book edition and patent status.
What is the main clinical advantage of gadoxetate disodium?
Its hepatobiliary uptake provides delayed-phase liver imaging that can improve detection and characterization of lesions with abnormal hepatocyte function.
Will generic gadoxetate disodium eliminate Bayer’s market?
Not necessarily. Generic entry would pressure price and share, but Bayer may retain volume through brand familiarity, supply reliability, clinical adoption, and institutional contracting.
Sources
- Bayer AG. (2023). Annual report 2023. Bayer AG.
- Bayer AG. (2024). Annual report 2024. Bayer AG.
- European Medicines Agency. (2024). Primovist: EPAR product information. European Medicines Agency.
- U.S. Food and Drug Administration. (2023). Eovist (gadoxetate disodium) prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Eovist application information. FDA.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent expiration resources. USPTO.
